|[January 11, 2013]
Research and Markets: Global Ophthalmic Drugs Market 2011-2015: Novartis AG and Pfizer Inc. Dominate the Market
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/mwvzrl/global_ophthalmic)
has announced the addition of the "Global
Ophthalmic Drugs Market 2011-2015" report to their offering.
TechNavio's analysts forecast the Global Ophthalmic Drugs market to grow
at a CAGR of 9.98 percent over the period 2011-2015. One of the key
factors contributing to this market growth is the increase in prevalence
of eye disorders. The Global Ophthalmic Drugs market has also been
witnessing the trend of increased focus on combination therapies.
However, the low patient compliance could pose a challenge to the growth
of this market.
This report has been prepared based on an in-depth market analysis with
inputs from industry experts. The report covers the Americas, and the
EMEA and APAC regions; it also covers the Global Ophthalmic Drugs market
landscape and its groth prospects in the coming years. The report also
includes a discussion of the key vendors operating in this market.
The key vendors dominating this market space are Alcon
Inc., Allergan, Inc., Merck and Co., Inc., Novartis AG, and Pfizer Inc.
Key questions answered in this report:
- What will the market size be in 2015 and what will the growth rate be
- What are the key market trends
- What is driving this market
- What are the challenges to market growth
- Who are the key vendors in this market space
- What are the market opportunities and threats faced by the key vendors
- What are the strengths and weaknesses of the key vendors
You can request one free hour of analyst time when you purchase this
report. Details provided within the report.
Commenting on the report, an analyst said: "There is an increase in the
use of fixed-combination therapies for the treatment of glaucoma.
Combination therapies significantly improve compliance by reducing the
number and frequency of eye drop applications. The vendors in the Global
Ophthalmic Drugs market are focusing more on the development of
combination therapies. This is evident from the strong pipeline of
combination therapies. Combination therapies are expected to reduce
inflammation, the possibility of choroidal neovascularization, and
vascular endothelial growth factor (VEGF) expression."
According to the report, one of the key drivers is the increasing
prevalence of eye disorders such as macular degeneration, diabetic
retinopathy (DR), and presbyopia in the elderly population. Moreover,
incidences of glaucoma and cataracts are increasing every year. Massive
numbers of people worldwide suffer from glaucoma, and this number is
expected to further increase by 2020. Across the globe, many people are
estimated to suffer from age-related macular degeneration (AMD (News - Alert)). The
incidence of AMD is expected to increase significantly during the
Further, the report reveals that one of the key challenges in this
market is low patient compliance.
The study was conducted using an objective combination of primary and
secondary information including inputs from key participants in the
industry. The report contains a comprehensive market and vendor
landscape in addition to a SWOT analysis of the key vendors.
For more information visit http://www.researchandmarkets.com/research/mwvzrl/global_ophthalmic.
[ Back To Technology News's Homepage ]